Dimethyl fumarate abrogates striatal endoplasmic reticulum stress in experimentally induced late-stage Huntington’s disease: Focus on the IRE1α/JNK and PERK/CHOP trajectories

Introduction: Dimethyl fumarate (DMF) is FDA-approved for use in patients with relapsing multiple sclerosis, and it processes neuroprotection in several experimental settings; however, its impact on combating Huntington’s disease (HD) remains elusive. This study aimed to explore the role of DMF post...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassab, Lina Y., Abbas, Samah S., Mohammed, Reham A., Abdallah, Dalaal M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088517/
https://www.ncbi.nlm.nih.gov/pubmed/37056990
http://dx.doi.org/10.3389/fphar.2023.1133863

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088517/
https://www.ncbi.nlm.nih.gov/pubmed/37056990
http://dx.doi.org/10.3389/fphar.2023.1133863

Ejemplares similares